Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2. A meta-analysis of published trials

《Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2. A meta-analysis of published trials》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、ProstateCancerandProstaticDisease(2013)16,323–327&2013MacmillanPublishersLimitedAllrightsreserved1365-7852/13www.nature.com/pcanORIGINALARTICLEArepost-docetaxeltreatmentseffectiveinpatientswithcastration-resistantprostatecancerandperformanceof2?Ameta-analysisofpublishedtrials11

2、23441RIacovelli,AAltavilla,GProcopio,SBracarda,MSantoni,SCascinuandECortesiBACKGROUND:About20%ofpatientswithprostatecancerhaveanECOGperformancestatus(PS)X2atdiagnosis.Weinvestigateifcurrenttreatmentoptionsforcastration-resistantprostatecancer(CRPC)maydecreasetheriskofdeatheveni

3、npatientswithECOGPSof2.METHODS:PubMedwasreviewedforphaseIIIrandomizedtrialsinpatientswithCRPCprogressedafterdocetaxelchemotherapy.Characteristicsofeachstudyandtherelativehazardratio(HR)foroverallsurvivaland95%confidenceinterval(CI)werecollected.SummaryHRwascalculatedusingrandom-

4、orfixed-effectsmodelsdependingontheheterogeneityofincludedstudies.RESULTS:Atotalof3,149patientswasavailableformeta-analysis.Intheoverallpopulation,theexperimentaltreatmentsdecreasetheriskofdeathby31%(HR¼0.69;95%CI:0.63–0.76;Po0.001).Theactivityofexperimentaltreatmentswassimilari

5、n2,859patientswithECOG-PS¼0or1withareducedriskofdeathof31%(HR¼0.69;95%CI:0.62–0.76).Atotalof290patients(9.2%)hadECOG-PS¼2andexperimentaltreatmentsdecreasedtheriskofdeathby26%(HR¼0.74;95%CI:0.56–0.98;P¼0.035)comparedwiththecontrolseveninthissub-group.Whenpatientswerestratifiedbyt

6、ypeoftreatment,thereductionoftheriskofdeathwasconfirmedforhormonaltherapies:abirateroneandenzalutamide(HR¼0.72;95%CI:0.52–0.99;P¼0.046),butnotforchemotherapy(HR¼0.81;95%CI:0.48–1.37;P¼0.43).CONCLUSIONS:Webelievethisisthefirststudyreportingabenefitinsecond-linesettingforCRPCpatient

7、spreviouslytreatedwithdocetaxelandpoorPS.ProstateCancerandProstaticDisease(2013)16,323–327;doi:10.1038/pcan.2013.20;publishedonline30July2013Keywords:castration-resistantprostatecancer;secondline;abirateroneacetate;cabazitaxel;enzalutamide;performancestatusINTRODUCTIONsoughttoi

8、nvestigatewhethercurrentavailabletreatmentsforProstate